Dr. Reddy's Subsidiary Aurigene Oncology, Announced Phase 1 Results For Ribrecabtagene Autoleucel From SWASTH Study; All 8 Patients Achieved Clinical Response
Portfolio Pulse from Benzinga Newsdesk
Aurigene Oncology, a subsidiary of Dr. Reddy's Laboratories, announced successful Phase 1 results for its CAR-T cell therapy, Ribrecabtagene autoleucel, in treating relapsed/refractory multiple myeloma. All 8 patients in the SWASTH study achieved clinical response, with no severe side effects reported.
October 08, 2024 | 10:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Dr. Reddy's Laboratories' subsidiary, Aurigene Oncology, reported 100% clinical response in Phase 1 trial for its CAR-T therapy, Ribrecabtagene autoleucel, in multiple myeloma patients. This could positively impact Dr. Reddy's stock due to promising trial results and potential future developments.
The successful Phase 1 trial results for Ribrecabtagene autoleucel, a novel CAR-T therapy, indicate a strong potential for future development and commercialization. This success could enhance Dr. Reddy's market position in oncology, likely leading to a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80